Literature DB >> 23123499

Signaling pathways bridging microbial-triggered inflammation and cancer.

Maulilio John Kipanyula1, Paul Faustin Seke Etet, Lorella Vecchio, Mohammed Farahna, Elias Nchiwan Nukenine, Armel Hervé Nwabo Kamdje.   

Abstract

Microbial-triggered inflammation protects against pathogens and yet can paradoxically cause considerable secondary damage to host tissues that can result in tissue fibrosis and carcinogenesis, if persistent. In addition to classical pathogens, gut microbiota bacteria, i.e. a group of mutualistic microorganisms permanently inhabiting the gastrointestinal tract and which plays a key role in digestion, immunity, and cancer prevention, can induce inflammation-associated cancer following the alterations of their microenvironment. Emerging experimental evidence indicates that microbiota members like Escherichia coli and several other genotoxic and mutagenic pathogens can cause DNA damage in various cell types. In addition, the inflammatory response induced by chronic infections with pathogens like the microbiota members Helicobacter spp., which have been associated with liver, colorectal, cervical cancers and lymphoma, for instance, can also trigger carcinogenic processes. A microenvironment including active immune cells releasing high amounts of inflammatory signaling molecules can favor the carcinogenic transformation of host cells. Pivotal molecules released during immune response such as the macrophage migration inhibitory factor (MMIF) and the reactive oxygen and nitrogen species' products superoxide and peroxynitrite, can further damage DNA and cause the accumulation of oncogenic mutations, whereas pro-inflammatory cytokines, adhesion molecules, and growth factors may create a microenvironment promoting neoplastic cell survival and proliferation. Recent findings on the implication of inflammatory signaling pathways in microbial-triggered carcinogenesis as well as the possible role of microbiota modulation in cancer prevention are herein summarized and discussed.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23123499     DOI: 10.1016/j.cellsig.2012.10.014

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  34 in total

Review 1.  Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.

Authors:  Jessica Tsuei; Thinh Chau; David Mills; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

Review 2.  Microbiota impact on the epigenetic regulation of colorectal cancer.

Authors:  Tao Yang; Jennifer L Owen; Yaíma L Lightfoot; Michael P Kladde; Mansour Mohamadzadeh
Journal:  Trends Mol Med       Date:  2013-09-16       Impact factor: 11.951

3.  Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor.

Authors:  Vinay Trivedi-Parmar; William L Jorgensen
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

Review 4.  Microbiota as a mediator of cancer progression and therapy.

Authors:  Jillian L Pope; Sarah Tomkovich; Ye Yang; Christian Jobin
Journal:  Transl Res       Date:  2016-08-03       Impact factor: 7.012

Review 5.  The microbiome and lung cancer.

Authors:  Abhiram Maddi; Amarpreet Sabharwal; Timothy Violante; Sunita Manuballa; Robert Genco; Santosh Patnaik; Sai Yendamuri
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

Review 6.  New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Authors:  Armel Hervé Nwabo Kamdje; Paul Faustin Seke Etet; Lorella Vecchio; Richard Simo Tagne; Jeremie Mbo Amvene; Jean-Marc Muller; Mauro Krampera; Kiven Erique Lukong
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

7.  Dihydromyricetin suppresses TNF-α-induced NF-κB activation and target gene expression.

Authors:  Nina Tang; Juan Ma; Ke Si Wang; Chunliu Mi; Ying Lv; Lian Xun Piao; Guang Hua Xu; Xuezheng Li; Jung Joon Lee; Xuejun Jin
Journal:  Mol Cell Biochem       Date:  2016-09-29       Impact factor: 3.396

Review 8.  Immune responses to Helicobacter pylori infection.

Authors:  Mati Moyat; Dominique Velin
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 9.  Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis?

Authors:  Jorge André Gomes Lopes; Marta Borges-Canha; Pedro Pimentel-Nunes
Journal:  World J Hepatol       Date:  2016-01-28

Review 10.  Streptococcal bacterial components in cancer therapy.

Authors:  Zeynab Marzhoseyni; Layla Shojaie; Seyed Alireza Tabatabaei; Ahmad Movahedpour; Mahmood Safari; Davoud Esmaeili; Maryam Mahjoubin-Tehran; Amin Jalili; Korosh Morshedi; Haroon Khan; Ranaa Okhravi; Michael R Hamblin; Hamed Mirzaei
Journal:  Cancer Gene Ther       Date:  2021-03-22       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.